Tripep AB (publ) - Interim Report for the period January-March 2002
Tripep AB (publ) - Interim Report for the period January-March 2002 · A pharmacological pig study designed to determine the best administration form for GPG® will be launched during the second quarter. · The CarryVac-HIV project has produced the first component of the vaccine currently being developed in cooperation with VRISD. Tests are being performed to analyze the efficacy of this component in neutralizing the HIV virus. · The restructuring work resulting from the company's new strategy has now been completed. Tripep is a biotech company that develops and commercializes candidate drugs